Have you ever had a health checkup that came back “normal,” yet you still felt fatigued, foggy, or out of balance?
Or known someone who was diagnosed with cancer shortly after receiving clear test results?
These situations highlight a crucial gap:
Traditional checkups are important—but they focus on detecting existing issues, not predicting future risks.
You may regularly undergo health checkups, including cancer markers and imaging scans.
Yet, it’s not uncommon to hear of individuals being diagnosed with cancer shortly after receiving “normal” test results. Why does this happen?
The truth is, traditional screenings, while essential, have their limitations.
Some risks remain hidden—undetectable by standard scans or blood markers—because they originate at a cellular or molecular level, far before tumors form.
This is where RGCC (Research Genetic Cancer Centre) testing plays a unique and valuable role.
One in three men and one in four women will be diagnosed with cancer in their lifetime. Many types of cancer can develop silently over years, and by the time symptoms appear, the disease may already be in an advanced stage. Recognizing early warning signs and seeking medical advice promptly can be life-changing.
Tumor markers are substances produced either by cancer cells or by the body in response to cancer. These can be found in blood, urine, stool, body fluids, or tissues.
For individuals who have experienced cancer, monitoring for recurrence or metastasis is a vital part of ongoing care.
While traditional imaging (like CT or MRI) can reveal tumor size and location, it often fails to detect the early biological activity of cancer cells.
This is where RGCC’s advanced circulating tumor cell (CTC) testing and genetic profiling offers a valuable advantage.
Onconomics Plus is an advanced personalized oncology assessment developed by RGCC.
In addition to testing the sensitivity of circulating tumor cells to various natural substances and pharmaceutical agents,
it also includes a range of key biomarkers closely associated with tumor behavior.
These biomarkers provide vital insights for designing personalized support strategies, risk evaluation, and ongoing monitoring.
Nutrition is more than food—it’s a form of strength, dignity, and healing. For cancer patients, especially those undergoing intense treatments or in advanced stages, eating can become a daily challenge. But with the right support, nutrition can become a powerful part of palliative care, helping patients feel better, stay stronger, and maintain comfort.
Living with cancer is never easy—but it doesn’t mean putting life on pause. For many people facing cancer, especially in advanced stages, the idea of “living well” takes on new meaning. Palliative care helps make that meaning real—by supporting comfort, dignity, and quality of life.
You’ve gone through chemotherapy. The recommended protocols were followed. But the tumor hasn’t responded as hoped. Naturally, you ask: Why didn’t it work? And what are the next options?
This is a question many cancer patients and families face. While it can feel disheartening, it’s important to remember that cancer is complex, and treatments can be complemented with additional insights to support better decisions ahead.
When cancer enters what is commonly referred to as the “stable phase,” many patients and their families may mistakenly believe that the disease is over and requires no further vigilance. However, in clinical practice, we often see that cancer cells can remain dormant for years and that metastasis may occur silently. This stage is, in fact, a critical window for prevention and monitoring.